How Novo Nordisk and Elil Lilly frame GLP-1 weight-loss drugs in corporate communications.

Summarise with VIRAT
Authors: Charlotte Nuijten, Luc L Hagenaars, Joreintje Dingena Mackenbach, Martijn Goudbeek
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This research analyzes how pharmaceutical companies Novo Nordisk and Eli Lilly framed obesity and GLP-1 weight-loss drugs (such as Wegovy and Zepbound) in their public communications between December 2017 and February 2026. With rising obesity rates – prevalence has nearly tripled since 1975, affecting over 650 million adults worldwide – this is an important societal issue. This study uses the 'commercial determinants of health' framework to understand how these companies defend their interests through reputational management and marketing. Through framing, selectively emphasizing certain aspects of reality, companies can portray obesity primarily as a medical problem requiring medication, thereby marginalizing preventive or behavioral interventions. The study collects documents such as press releases, annual reports, CEO interviews, and social media posts, analyzing them qualitatively using Entman's framework: how do the companies define the problem, what do they identify as causes, how do they evaluate it morally, and what solutions do they propose? The goal is to gain insight into how commercial actors shape public discourse around obesity, enabling policymakers and healthcare professionals to critically evaluate this influence.

Fields of Study & Subjects

Global Public Health Policies and Epidemiology Obesity and Health Practices Pharmaceutical industry and healthcare

Publication details

Journal / source
OSF Preprints (OSF Preprints)
Publication date
18 March 2026
Language
EN
Document type
Preprint